CO-TECHSTARS
Techstars, a global investment business that provides access to capital, one-on-one mentorship, and customized programming for early-stage entrepreneurs, announces two strategic and operational leaders who will join the global management team effective immediately. Aparna Ramaswamy will serve as the new Chief Human Capital Officer and Kimberly Smith has been appointed to the newly formed role as Chief Capital Formation Officer, both positions report to CEO, Maëlle Gavet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220420005309/en/
“The best capital - whether human or financial - will pave the way for Techstars in its ambition to become the largest pre-seed investor," said Gavet. "These two deeply talented and experienced operational leaders will help Techstars continue its growth worldwide for our proven and scalable investment business."
As the new Chief Human Capital Officer, Ramaswamy has experience across a diverse portfolio of global businesses and industries/sectors including financial services, oil and gas, security, aviation, and public education. She has a recognized track record of shaping change through a strategic approach of aligning people and culture to enable businesses to scale and solve complex problems. In her most recent role as Chief Human Capital Officer for Success Academy Charter Schools in New York City, she introduced an innovative two-year leadership fellows program (Robertson Leadership Fellows) to accelerate and build the school leadership pipeline at scale and also created and led the first Inclusion Council and DEI commitments for a network of 47 public charter schools serving 20,000 children across four NYC boroughs. With Techstars’ recent announcement , launching nine diverse-led accelerators programs in partnership with J.P. Morgan, Ramaswamy’s experience in building and leading DE&I related initiatives at scale will be invaluable to the organization.
Prior to her most recent leadership role with Success Academy Charter Schools, Ramaswamy served as Co-Head of Human Resources at Bridgewater Associates and before that, spent 14 years at General Electric (GE) in progressively larger global Human Resources leadership roles across multiple businesses and industries. Based in Stamford, Connecticut, she plans to bring to Techstars her broad and varied range of global experience in talent acquisition, leadership capacity building, talent management, and total rewards, to reinforce operational excellence and deliver on Techstars’ key strategic objectives.
Ramaswamy received a Bachelor of Arts in Sociology and Psychology from St. Xavier’s College in Mumbai, India, a Master of Arts in Sociology from the University of Mumbai, India, and a Master of Business Administration from the University of Michigan Ross School of Business. In her free time, she serves on the American India Foundation Tri-State Board and is a member of the Vitalize VC Angels investment community, and the Chief Network.
Named as Techstars’ first Chief Capital Formation Officer, Smith joined the company in September 2021 and immediately began making an impact through her influence with prospective and existing investors and Limited Partners (LPs). She was integral in helping the organization close the Advancing Cities fund last month.
Based in New York City, she will be responsible for Tecshstars’ fundraising and investor relations while cultivating relationships with current and future investors - both traditional institutional LPs as well as individuals and strategic investors. Smith has spent her career raising money in the investment management sector and before joining Techstars, spent 15+ years with Owl Creek Asset Management, a NY-based event driven hedge fund, where she was a Partner and responsible for raising and retaining billions of investor capital. She has also held leadership positions in Investor Relations and Marketing at Davidson Kempner, traded coffee and sugar in the Global Futures group at ABN AMRO and got her start in finance working at Ziff Brothers.
Smith received her Bachelor of Arts from Middlebury College and her Masters of Business Administration from Fordham University. She is also the Chair of both the Board of Trustees and the Investment Committee at the Ethical Culture Fieldston School in New York City.
Following four other executive appointments within the last year, Techstars is taking bold and ambitious steps toward bringing together an industry team of leaders focused on building and growing a world-class investment business at scale.
About Techstars
The Techstars worldwide network helps entrepreneurs succeed. Founded in 2006, Techstars began with three simple ideas—entrepreneurs create a better future for everyone, collaboration drives innovation, and great ideas can come from anywhere. Now we are on a mission to enable every person on the planet to contribute to, and benefit from, the success of entrepreneurs. In addition to operating accelerator programs and venture capital funds, we do this by connecting startups, investors, corporations, and cities to help build thriving startup communities. Techstars has invested in more than 3,000 companies with a combined market cap of more than $172B. www.techstars.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220420005309/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
